• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pretreatment high cholesterol and low neutrophils predict complete pathological response after neoadjuvant short‑course radiotherapy followed by chemotherapy and immunotherapy in locally advanced rectal cancer.在局部晚期直肠癌患者中,新辅助短程放疗后序贯化疗和免疫治疗,治疗前高胆固醇血症和低中性粒细胞计数可预测完全病理缓解。
Oncol Lett. 2023 Jun 7;26(1):319. doi: 10.3892/ol.2023.13905. eCollection 2023 Jul.
2
Current status of neoadjuvant therapy for locally advanced rectal cancer in Wuhan Union Hospital Cancer Center.武汉协和医院肿瘤中心局部进展期直肠癌新辅助治疗的现状。
Radiat Oncol. 2022 Jun 20;17(1):109. doi: 10.1186/s13014-022-02081-8.
3
Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.局部进展期直肠癌新辅助短程放疗或放化疗后延迟手术的病理完全缓解率比较。
Eur J Surg Oncol. 2018 Jul;44(7):1013-1017. doi: 10.1016/j.ejso.2018.03.014. Epub 2018 Mar 23.
4
Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial.术前短程放疗序贯新辅助化疗治疗局部进展期直肠癌的剂量递增:一项开放标签、单中心、I 期临床试验方案。
BMJ Open. 2019 Mar 23;9(3):e025944. doi: 10.1136/bmjopen-2018-025944.
5
[Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].短程放疗联合CAPOX和PD-1抑制剂用于局部晚期直肠癌的全新辅助治疗:一项前瞻性、多中心、随机II期试验(TORCH)的单中心初步研究结果
Zhonghua Wei Chang Wai Ke Za Zhi. 2023 May 25;26(5):448-458. doi: 10.3760/cma.j.cn441530-20230107-00010.
6
[Application of short-course radiotherapy with total neoadjuvant therapy in the treatment of middle and low rectal cancer].短程放疗联合全新辅助治疗在中低位直肠癌治疗中的应用
Zhonghua Yi Xue Za Zhi. 2023 Jan 31;103(4):271-277. doi: 10.3760/cam.j.cn112137-20220514-01055.
7
Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.短程放疗序贯 mFOLFOX-6 联合avelumab 治疗局部进展期直肠腺癌。
BMC Cancer. 2020 Sep 1;20(1):831. doi: 10.1186/s12885-020-07333-y.
8
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值作为接受新辅助放化疗的局部晚期直肠癌患者的预测和预后标志物。
BMC Cancer. 2019 Jul 5;19(1):664. doi: 10.1186/s12885-019-5892-x.
9
Predicting Pathological Complete Regression with Haematological Markers During Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.新辅助放化疗期间利用血液学标志物预测局部晚期直肠癌的病理完全缓解
Anticancer Res. 2018 Dec;38(12):6905-6910. doi: 10.21873/anticanres.13067.
10
Can pretreatment blood biomarkers predict pathological response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer?新辅助放化疗治疗局部进展期直肠癌患者的术前血液生物标志物能否预测病理缓解?
Future Oncol. 2021 Dec;17(35):4947-4957. doi: 10.2217/fon-2021-0707. Epub 2021 Nov 4.

引用本文的文献

1
Neoadjuvant chemoradiotherapy with or without preoperative immunotherapy for locally advanced rectal cancer: a system review and meta-analysis.局部晚期直肠癌新辅助放化疗联合或不联合术前免疫治疗:一项系统评价和荟萃分析
Updates Surg. 2025 Jul 5. doi: 10.1007/s13304-025-02309-8.
2
Prophylactic antibiotic use is associated with better clinical outcomes in gastric cancer patients receiving immunotherapy.在接受免疫治疗的胃癌患者中,预防性使用抗生素与更好的临床结局相关。
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyae362.

本文引用的文献

1
The Pre-Treatment Platelet-to-Lymphocyte Ratio as a Prognostic Factor for Loco-Regional Control in Locally Advanced Rectal Cancer.治疗前血小板与淋巴细胞比值作为局部晚期直肠癌局部区域控制的预后因素
Diagnostics (Basel). 2023 Feb 11;13(4):679. doi: 10.3390/diagnostics13040679.
2
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.《直肠癌(2022 年第 2 版)》,美国国家综合癌症网络(NCCN)肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2022 Oct;20(10):1139-1167. doi: 10.6004/jnccn.2022.0051.
3
Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.治疗前和治疗中乳酸脱氢酶作为晚期非小细胞肺癌的预后和预测生物标志物。
Cancer. 2022 Apr 15;128(8):1574-1583. doi: 10.1002/cncr.34113. Epub 2022 Jan 28.
4
Anal preservation on the psychology and quality of life of low rectal cancer.保肛对低位直肠癌患者心理和生活质量的影响。
J Surg Oncol. 2022 Mar;125(3):484-492. doi: 10.1002/jso.26741. Epub 2021 Nov 9.
5
Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer.术前短程放疗联合化疗和卡瑞利珠单抗治疗局部进展期直肠癌的 II 期单臂临床试验。
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003554.
6
Neutrophils in cancer carcinogenesis and metastasis.中性粒细胞在癌症发生和转移中的作用。
J Hematol Oncol. 2021 Oct 21;14(1):173. doi: 10.1186/s13045-021-01187-y.
7
Pretreatment Neutrophil-to-Lymphocyte Ratio Associated with Tumor Recurrence and Survival in Patients Achieving a Pathological Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer.新辅助放化疗后达到病理完全缓解的直肠癌患者,治疗前中性粒细胞与淋巴细胞比值与肿瘤复发及生存的关系
Cancers (Basel). 2021 Sep 13;13(18):4589. doi: 10.3390/cancers13184589.
8
Neoadjuvant Modified Short-Course Radiotherapy Followed by Delayed Surgery for Locally Advanced Rectal Cancer.新辅助改良短程放疗后延迟手术治疗局部晚期直肠癌。
Cancers (Basel). 2021 Aug 15;13(16):4112. doi: 10.3390/cancers13164112.
9
Clinicopathological significance of neutrophil-rich colorectal carcinoma.富含中性粒细胞的结直肠癌的临床病理意义。
J Clin Pathol. 2023 Jan;76(1):34-39. doi: 10.1136/jclinpath-2021-207702. Epub 2021 Jul 26.
10
Neutrophil Extracellular Traps in Colorectal Cancer Progression and Metastasis.中性粒细胞胞外陷阱在结直肠癌进展和转移中的作用。
Int J Mol Sci. 2021 Jul 6;22(14):7260. doi: 10.3390/ijms22147260.

在局部晚期直肠癌患者中,新辅助短程放疗后序贯化疗和免疫治疗,治疗前高胆固醇血症和低中性粒细胞计数可预测完全病理缓解。

Pretreatment high cholesterol and low neutrophils predict complete pathological response after neoadjuvant short‑course radiotherapy followed by chemotherapy and immunotherapy in locally advanced rectal cancer.

作者信息

Zhang Fangyuan, Yu Dandan, Yang Jinru, Zhai Menglan, Li Lisha, Zhao Lei, Wang Jing, Zhang Tao, Lin Zhenyu

机构信息

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.

Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.

出版信息

Oncol Lett. 2023 Jun 7;26(1):319. doi: 10.3892/ol.2023.13905. eCollection 2023 Jul.

DOI:10.3892/ol.2023.13905
PMID:37332340
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10272967/
Abstract

The present study was aimed at looking for hematological indicators that could predict pathological complete response (pCR) in patients with locally advanced rectal cancer (LARC) treated with short-course radiotherapy (SCRT) followed by chemotherapy and immunotherapy. A total of 171 patients were enrolled in this observational retrospective study. Pretreatment values of albumin, total cholesterol, lactate dehydrogenase, neutrophil, platelet and lymphocytes were available. Univariate and multivariate logistics analyses were used to determine the prognostic factor for pCR. SCRT followed by chemotherapy and immunotherapy was demonstrated to double the pCR rate (50.5%) compared with long-course chemoradiotherapy. For the former group, baseline high platelet to lymphocyte ratio (P=0.047), high cholesterol (P=0.026) and low neutrophils (P=0.012) level were associated with high pCR rate and baseline high cholesterol (P=0.016) and low neutrophils (P=0.020) level were the independent prognostic factors for pCR. In conclusion, pretreatment high cholesterol and low neutrophils were the independent prognostic predictors of pCR in patients with LARC treated with SCRT followed by chemotherapy and immunotherapy. Clinical trial no. NCT04928807, June 16, 2021.

摘要

本研究旨在寻找血液学指标,以预测接受短程放疗(SCRT)后序贯化疗和免疫治疗的局部晚期直肠癌(LARC)患者的病理完全缓解(pCR)情况。共有171例患者纳入了这项观察性回顾性研究。可获取白蛋白、总胆固醇、乳酸脱氢酶、中性粒细胞、血小板和淋巴细胞的治疗前数值。采用单因素和多因素逻辑回归分析来确定pCR的预后因素。与长程放化疗相比,SCRT后序贯化疗和免疫治疗使pCR率翻倍(50.5%)。对于前一组,基线高血小板与淋巴细胞比值(P = 0.047)、高胆固醇(P = 0.026)和低中性粒细胞水平(P = 0.012)与高pCR率相关,且基线高胆固醇(P = 0.016)和低中性粒细胞水平(P = 0.020)是pCR的独立预后因素。总之,在接受SCRT后序贯化疗和免疫治疗的LARC患者中,治疗前高胆固醇和低中性粒细胞是pCR的独立预后预测指标。临床试验编号:NCT04928807,2021年6月16日。